product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
JNK1 (2C6) Mouse mAb
catalog :
3708
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
2C6
reactivity :
human, mouse, rat
application :
western blot
citations: 20
Published Application/Species/Sample/DilutionReference
  • western blot; mouse; loading ...; fig 3b
Salomè M, Magee A, Yalla K, Chaudhury S, Sarrou E, Carmody R, et al. A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling. Cell Death Dis. 2018;9:443 pubmed publisher
  • western blot; mouse; 1:1000; loading ...; fig 3d
Nishimura S, Mishra Gorur K, Park J, Surovtseva Y, Sebti S, Levchenko A, et al. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. Proc Natl Acad Sci U S A. 2017;114:5503-5508 pubmed publisher
  • western blot; mouse; loading ...; fig s2a
Daley D, Mani V, Mohan N, Akkad N, Ochi A, Heindel D, et al. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat Med. 2017;23:556-567 pubmed publisher
  • western blot; human; fig 2
Trapé A, Liu S, Cortés A, Ueno N, Gonzalez Angulo A. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. J Cancer. 2016;7:947-56 pubmed publisher
  • western blot; human; fig 4
Choi H, Kim M, Choi Y, Shin Y, Cho S, Ko S. Rhus verniciflua Stokes (RVS) and butein induce apoptosis of paclitaxel-resistant SKOV-3/PAX ovarian cancer cells through inhibition of AKT phosphorylation. BMC Complement Altern Med. 2016;16:122 pubmed publisher
  • western blot; human; loading ...; fig 3a
Lv H, Zhang Z, Wu X, Wang Y, Li C, Gong W, et al. Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent. PLoS ONE. 2016;11:e0145195 pubmed publisher
  • western blot; rat; fig s5
Wang J, Cao Y, Li Q, Yang Y, Jin M, Chen D, et al. A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation. Autophagy. 2015;11:2057-2073 pubmed publisher
  • western blot; human; 1:1000
Benzina S, Pitaval A, Lemercier C, Lustremant C, Frouin V, Wu N, et al. A kinome-targeted RNAi-based screen links FGF signaling to H2AX phosphorylation in response to radiation. Cell Mol Life Sci. 2015;72:3559-73 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 7e
Salvucci O, Ohnuki H, Maric D, Hou X, Li X, Yoon S, et al. EphrinB2 controls vessel pruning through STAT1-JNK3 signalling. Nat Commun. 2015;6:6576 pubmed publisher
  • western blot; mouse; 1:1000; fig 5a
Wei Z, Yu D, Bi Y, Cao Y. A disintegrin and metalloprotease 17 promotes microglial cell survival via epidermal growth factor receptor signalling following spinal cord injury. Mol Med Rep. 2015;12:63-70 pubmed publisher
  • western blot; human; 1:1000; fig s2
Tsoi H, Yu A, Chen Z, Ng N, Chan A, Yuen L, et al. A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia. J Med Genet. 2014;51:590-5 pubmed publisher
  • western blot; human
George S, Vishwamitra D, Manshouri R, Shi P, Amin H. The ALK inhibitor ASP3026 eradicates NPM-ALK? T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget. 2014;5:5750-63 pubmed
  • western blot; human
Weilbacher A, Gutekunst M, Oren M, Aulitzky W, van der Kuip H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 2014;5:e1318 pubmed publisher
  • western blot; mouse
Tamaki S, Tokumoto Y. Overexpression of cyclin dependent kinase inhibitor P27/Kip1 increases oligodendrocyte differentiation from induced pluripotent stem cells. In Vitro Cell Dev Biol Anim. 2014;50:778-85 pubmed publisher
Ebelt N, Kaoud T, Edupuganti R, Van Ravenstein S, Dalby K, Van Den Berg C. A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget. 2017;8:104894-104912 pubmed publisher
Sheng X, You Q, Zhu H, Chang Z, Li Q, Wang H, et al. Bacterial effector NleL promotes enterohemorrhagic E. coli-induced attaching and effacing lesions by ubiquitylating and inactivating JNK. PLoS Pathog. 2017;13:e1006534 pubmed publisher
Choi H, Lee K, Kim M, Lee K, Shin Y, Cho S, et al. DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis. Oncotarget. 2016;7:21775-85 pubmed publisher
Shin J, Chun K, Na Y, Song K, Kim S, Lim J, et al. Allopurinol Protects against Ischemia/Reperfusion-Induced Injury in Rat Urinary Bladders. Oxid Med Cell Longev. 2015;2015:906787 pubmed publisher
Nori S, Rocco M, Florenzano F, Ciotti M, Aloe L, Manni L. Increased nerve growth factor signaling in sensory neurons of early diabetic rats is corrected by electroacupuncture. Evid Based Complement Alternat Med. 2013;2013:652735 pubmed publisher
Vishwamitra D, Li Y, Wilson D, Manshouri R, Curry C, Shi B, et al. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am J Pathol. 2012;180:1772-80 pubmed publisher
product information
SKU :
3708S
Product-Name :
JNK1 (2C6) Mouse mAb
Size :
100 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, M, R, Mk
Applications :
Western blot
Product-Category :
MAP Kinase Signaling
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
46, 54
Host :
Mouse
Target :
SAPK/JNK1
Primary-Protein :
JNK1
Alt-Names :
JNK,JNK-46,JNK1,JNK1 alpha protein kinase,JNK1 beta protein kinase,JNK1A2,JNK21B1/2,JUN N-terminal kinase,MAP kinase 8,MAPK 8,MAPK8,MK08,Mitogen-activated protein kinase 8,PRKM8,SAPK1,Stress-activated protein kinase 1,Stress-activated protein kinase JNK1,c-Jun N-terminal kinase 1,mitogen-activated protein kinase 8 isoform JNK1 alpha1,mitogen-activated protein kinase 8 isoform JNK1 beta2,protein kinase JNK1
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.